Features
Diagnosing and Managing Polypoidal Choroidal Vasculopathy
Evidence-based strategies for diagnosis and therapeutic decision-making.
By Giulia Gregori, MD, Jay Chhablani, MD
Dual-Pathway Gene Therapy for Geographic Atrophy
An approach currently being investigated would combine neuroprotection and complement modulation.
By Thomas A. Ciulla, MD, MBA
The Evolving TKI Pipeline
Several agents are being investigated for durability and clinical potential in retinal vascular disease.
By Simrat K. Sodhi, MSc, MB BChir (Cantab), David S. Boyer, MD
The Therapeutic Pipeline for Geographic Atrophy
Reviewing the next wave of clinical-stage therapies in development for GA.
By Benedict Uzorka, BS, Jessica D. Randolph, MD
Departments
The Excitement of Clinical Trials
Upfront: The March/April issue has a focus on age-related macular degeneration.
By Diana V. Do, MD
Can Photobiomodulation Regulate Dry AMD?
Controversies in Care: Evaluating whether evidence for PBM reflects a true treatment effect or arises from natural variability.
By Tiago Rassi, MD, Daniel M. Berinstein, MD, Michael Colucciello, MD
Why Uveitis Fellowship Deserves a Second Look
Uveitis Corner: Survey data and specialist insights challenge long-standing misconceptions about uveitis training, surgery, and compensation.
By John A. Gonzales, MD , Jessica Shantha, MD, Sruthi Arepalli, MD, et al.
Coding Wet and Dry AMD
Coding Q&A: Key distinctions in ICD-10 coding for wet and dry AMD to prevent denials and delays.
By Elizabeth Cifers, MBA, MSW, CHC, CPC
Clinical Trial Update March 2026
Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.
News
Axpaxli Could Transform Wet AMD Care
Retina Conversations: Ocular Therapeutics head Pravin U. Dugel, MD, explains SOL-1 trial results and how Axpaxli could reshape wet AMD treatment.
By Pravin U. Dugel, MD